Emergent BioSolutions, Inc., begins construction of new Michigan facilities

Emergent BioSolutions, Inc., the makers of the only FDA-approved anthrax vaccine, BioThrax, recently broke ground on the first phase of a five year overhaul of its Lansing, Michigan, facilities.

The beginning of the $108 million project was marked by a ceremony attended by Emergent BioSolutions Inc., employees, President and CEO Daniel J. Abdun Nabi, Michigan Lt. Governor Brian Calley, Lansing Mayor Virg Bernero and a host of other state and city officials, according to MLive.com.

"Emergent BioSolutions is deeply rooted in the Lansing community, from where our operations have expanded globally through the years. We are committed to mid-Michigan and look forward to working with the city and state to support our growth plans," Abdun-Nabi said, MLive.com reports.

The first phase of the project centers around the construction of a three story, 32,000-square-foot administration building that will house modern offices, a cafeteria and fitness center. An additional $4 million worth of improvements will be made to the rest of the campus during the same phase.

The next portion of the improvement plans call for the construction of a new cold storage and supply chain warehouse and additional improvements to existing buildings and office. There are also plans to construct a new research facility and to upgrade the campus power plant.

Michigan state and Lansing-area tax incentives will refund Emergent BioSolutions, Inc., approximately $5.7 million as a reimbursement for environmental cleanup and public infrastructure costs.

The biodefense company was recently awarded a five year, $1.25 billion contract to produce BioThrax for the federal government.